Zobrazeno 1 - 9
of 9
pro vyhledávání: '"O P Nikolin"'
Publikováno v:
Системные гипертензии, Vol 11, Iss 3, Pp 74-80 (2014)
According to the 2013 ESH guidelines, it is possible to use any group of known antihypertensive drugs in the treatment of arterial hypertension. But we often have been using different combinations of drugs. In this situation, using drugs combination
Externí odkaz:
https://doaj.org/article/201cf47e68fa40979033a07289c83e4c
Publikováno v:
Системные гипертензии, Vol 11, Iss 1, Pp 34-39 (2014)
The arterial hypertension takes the basic place among the cardiovascular diseases which are a principal cause of death and invalidity. For today the basic group for treatment of an arterial hypertensia remain angiotensin-converting enzyme inhibitors
Externí odkaz:
https://doaj.org/article/11346e8dfb5a4aa08b4638142aa4fff9
Autor:
O. S. Ivanova, E. Y. Maychuk, I. V. Voevodina, I. A. Makarova, E. V. Akatova, A. I. Zavyalova, O. P. Nikolin
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 3, Pp 62-67 (2023)
Objective: study of the relationship between arterial hypertension and arterial stiffness in women to identify potential markers of target organ damage and therapeutic targets of antihypertensive therapy.Materials and methods: the study involved 161
Externí odkaz:
https://doaj.org/article/d0e939c15fe845aba9135dcf00b12f1d
Publikováno v:
Радиационная гигиена, Vol 9, Iss 4, Pp 87-92 (2017)
The goal of the research is to determine relationship between tritium concentration in the body fluid (urine) of people living in the area of influence of the Beloyarskaya NPP and tritium concentration in drinking water.Materials and methods. Studed
Externí odkaz:
https://doaj.org/article/840773841b904134b3eeff5e2e630f04
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 11, Iss 3, Pp 30-35 (2012)
Aim. To assess the effectiveness of long-term treatment with magnesium orotate (Magnerot®), as a pathogenetic therapy, in patients with mitral valve prolapse (MVP). Material and methods. In total, 31 MVP patients, administered Magnerot® (1500 mg/d)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f968da9c862a6484548dfcd5b17ee558
https://doi.org/10.15829/1728-8800-2012-3-30-35
https://doi.org/10.15829/1728-8800-2012-3-30-35
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 9, Iss 1, Pp 64-68 (2010)
Aim. To assess quality of life (QoL) and severity of vegetative dysfunction syndrome (VDS) in patients with idiopathic mitral valve prolapse (MVP); to evaluate the effects of alprazolam therapy on QoL and VDS. Material and methods. This single-blind,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::63e14c1997c7795a958bc6b604cebcbd
https://cardiovascular.elpub.ru/jour/article/view/2016
https://cardiovascular.elpub.ru/jour/article/view/2016
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 8, Iss 8, Pp 9-12 (2009)
Aim. To evaluate the effectiveness of magnesium orotate in the patients with cardiac arrhythmias, arterial hypertension (AH), and idiopathic mitral valve prolapse (MVP). Material and methods. The complex examination, dynamic follow-up, and placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::0a54052e86698155deea31afa448430c
https://cardiovascular.elpub.ru/jour/article/view/1351
https://cardiovascular.elpub.ru/jour/article/view/1351
Autor:
A I, Martynov, O P, Nikolin
Publikováno v:
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimentalclinical gastroenterology. (1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::61a524339f0b7423536472fc1d852d03
https://pubmed.ncbi.nlm.nih.gov/19145853
https://pubmed.ncbi.nlm.nih.gov/19145853
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 11, Iss 3, Pp 30-35 (2012)
Aim. To assess the effectiveness of long-term treatment with magnesium orotate (Magnerot®), as a pathogenetic therapy, in patients with mitral valve prolapse (MVP). Material and methods. In total, 31 MVP patients, administered Magnerot® (1500 mg/d)
Externí odkaz:
https://doaj.org/article/829d59c38b704dae93b38015c21051e2